Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on assets-58.6%
Liquidity
Current ratio8.2×-0.5×8.6×-3.0×11.6×-2.2×13.8×-0.1×13.9×
Quick ratio8.2×-0.5×8.6×-3.0×11.6×-2.2×13.8×-0.1×13.9×
Cash ratio-0.1×2.1×-0.3×2.3×-0.4×2.7×+0.2×2.5×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.1×0.0×0.1×
Debt-to-assets0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.1×
Per Share
Book value per share$3.56-20.9%$4.50-14.8%$5.28-13.7%$6.11-11.8%$6.93-58.2%
Valuation
Market capitalization$429.03M+1,015%$105.3M+50.2%$70.1M
Enterprise value$417.88M+1,832%$89.08M+59.6%$55.82M
Price / book4.9×+4.7×+0.4×0.5×
Free cash flow yield-18.7%+140pp-75.3%+37.2pp-112.6%
Earnings yield-20.3%+166pp-79.6%+33.3pp-113%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Artiva Biotherapeutics, Inc.'s ratios come from?
Every ratio is computed from Artiva Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.